Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 02

128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study

Date

03 Dec 2022

Session

Poster viewing 02

Presenters

Dawn Lynn Guardiario

Citation

Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1016/annonc/annonc1123

Authors

D.L.P. Guardiario, C. Dy

Author affiliations

  • Medical Oncology Department, St. Luke's Medical Center - Quezon City, 1112 - Quezon City/PH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 128P

Background

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related deaths in the world. Gastric cancer still constitutes a major global health problem in Asian countries; however there is limited data of the clinical outcome of gastric cancer in the Philippines. Thus this study aimed to determine the survival outcome of gastric adenocarcinoma patients in our institution.

Methods

This was a single-center 10-year retrospective study of gastric adenocarcinoma patients in our institution from January 2010 to December 2019. Categorical data were reported as number with percentage and continuous variables were reported as median. Survival outcomes were calculated using Kaplan-Meier method. Cox proportional hazards (PH) model was used to estimate the effect of variables on event-free survival (EFS) and overall survival (OS). P value of < 0.05 was set to indicate a statistically significant difference.

Results

Median age of diagnosis was 57 years old (range 20 to 86 years old). The majority (78%) of patients were younger than 70 years old and majority were males (62.1%). Abdominal pain was the most common presenting symptom. Patients had stage III (25.8%) and stage IV (54.5%) at diagnosis. Liver was the most common site of metastasis. Most gastric lesions were located at the proximal third (cardia and gastroesophageal area), poorly differentiated, diffuse type, Her2 negative, H.pylori negative. Majority of patients had normal body mass index, no comorbidities, and were non-smokers. Median overall event-free survival (EFS) for all patients was 7.1 months (95% CI 4.8 to 9.4) and median overall survival (OS) was 8.7 months (95% CI 6.4 to 11.1). Using multivariable analysis, the predictors for both EFS and OS were stage at diagnosis, Lauren’s histologic classification and smoking status.

Conclusions

Survival outcome of gastric cancer patients in our institution is similar to that in other Asian countries. Advanced stage at diagnosis was largely responsible for low survival. Early screening and patient education are needed to help improve survival outcome.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.